Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: A double-blind, randomized, controlled study

Journal of International Medical Research

Volumn 39, Issue 2, 2011, Pages 358-365

  Li, X ^a   Zhang, N ^a   Li, Y ^a   Shi, Y ^a   Li, D ^a   Xie, Y ^a,b   Ming, J ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Insulin resistance; Metformin; Obesity; Rosiglitazone; cell Function

Indexed keywords

CHOLESTEROL; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ADULT; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BODY FAT; BODY MASS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART FAILURE; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET CELL FUNCTION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; WEAKNESS;

EID: 79955673061     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900203     Document Type: Article

References (24)

1. Wild S, Roglic G, Green A, et al: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. National Bureau of Statistics of China: China Statistical Yearbook-2006. Beijing: China Statistics Press, 2006 (available at: http://www.stats.gov.cn/tjsj/ndsj/2006/indexeh.htm).
3. Pan XR, Yang WY, Li GW, et al: Prevalence of diabetes and its risk factors in China, 1994. Diabetes Care 1997; 20: 1664-1669.
4. Wu Y: Editorial: overweight and obesity in China. BMJ 2006; 333: 362-363.
5. Ge K: The status and trends of obesity in China. Int J Vitam Nutr Res 2006; 76: 247-252.
6. Modan M, Halkin H, Almog S, et al: Hyperinsulinemia. A link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-817.
7. Tripathy D, Carlsson M, Almgren P, et al: Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 2000, 49: 975-980.
8. Wang Y, Mi J, Shan XY, et al: Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007; 31: 177-188.
9. Freemark M, Bursey D: The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107: E55.
10. Morrison JA, Cottingham EM, Barton BA: Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002; 159: 655-657.
11. Wagstaff AJ, Goa KL: Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-1837.
12. Derosa G, Salvadeo SA, D'Angelo A, et al: Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. Arch Med Res 2008; 39: 412-419.
13. Ministry of Health Disease Control Division: Chinese Adults Overweight and Obesity Prevention and Control Guidelines (Trial) [M]. Beijing: Ministry of Health, 2003; pp 3-5 [in Chinese].
14. Trinder P: Determination of blood glucose using an oxidase-peroxidase system with noncarcinogenic chromogen. J Clin Pathol 1969; 22: 158-161.
15. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
16. Püttmann M, Krug H, von Ochsenstein, et al: Fast HPLC determination of serum free fatty acids in the picomole range. Clin Chem 1993; 39: 825-832.
17. Shiwaku K, Anuurad E, Enkhmaa B, et al: Appropriate BMI for Asian populations. Lancet 2004; 363: 1077.
18. Reynolds K, Gu D, Whelton PK, et al: Prevalence and risk factors of overweight and obesity in China. Obesity (Silver Spring) 2007; 15: 10-18.
19. Bell C, Ge K: The road to obesity or the path to prevention: motorized transportation and obesity in China. Obesity Res 2002; 10: 277-283.
20. Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med 2002; 137: 25-33.
21. Grant PJ: The effects of high-and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996; 19: 64-66.
22. Yamauchi T, Kamon J, Waki H et al: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor p (PPAR() deficiency and PPAR))agonist improve insulin resistance. J Biol Chem 2001; 276: 41245-41254.
23. Hung YJ, Lin SH, Pei D, et al: Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. Metabolism 2006; 55: 439-444.
24. Osei K, Gaillard T, Kaplow J, et al: Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism 2004; 53: 1552-1557.